Cost of SARMs: What You Actually Pay, What You Risk, and What Compounded Alternatives Cost

What Are SARMs and Why Do People Buy Them?

SARMs are a class of molecules designed to bind androgen receptors in muscle and bone while theoretically sparing the prostate and other tissues from androgenic side effects. The concept originated in oncology research during the 1990s, aimed at treating muscle wasting and osteoporosis without the full androgenic burden of testosterone. Not one SARM compound has cleared FDA approval for any clinical indication as of July 2025.

Despite that, online vendors market compounds like ostarine (MK-2866), ligandrol (LGD-4033), and testolone (RAD-140) directly to athletes and body-composition clients. The pitch is simple: anabolic gains, fewer side effects than steroids, no prescription needed. The reality is considerably messier.

A 2017 analysis published in JAMA by Van Wagoner et al. tested 44 SARM products purchased from online retailers. Only 52 percent actually contained a SARM. About 39 percent contained an unapproved drug, 25 percent contained substances not listed on the label, and 9 percent contained no active ingredient at all (1). Those numbers have not meaningfully improved in follow-up surveys.

The FDA has issued more than 41 warning letters, import alerts, and public advisories related to SARMs since 2017, explicitly cautioning that products marketed for human consumption containing SARMs may be seized at the border and that sellers may face criminal prosecution (2).

How Much Do SARMs Actually Cost?

Prices vary widely, and stacking multiple compounds is common, which multiplies total monthly spend fast.

The table below reflects current retail pricing across major grey-market vendors as of mid-2025. Prices are per month at commonly marketed doses.

| Compound | Common Marketed Dose | Estimated Monthly Cost | |---|---|---| | Ostarine (MK-2866) | 10 to 25 mg/day | $40 to $70 | | Ligandrol (LGD-4033) | 5 to 10 mg/day | $50 to $80 | | Testolone (RAD-140) | 10 to 20 mg/day | $60 to $100 | | Cardarine (GW-501516) | 10 to 20 mg/day | $45 to $75 | | Ibutamoren (MK-677) | 10 to 25 mg/day | $50 to $90 | | YK-11 | 5 to 10 mg/day | $70 to $150 |

A single-compound "beginner" cycle of ostarine for 8 weeks runs $80 to $140 total. Users who stack two or three compounds for 12 weeks can spend $300 to $600, not counting the post-cycle therapy (PCT) many then purchase. Common PCT protocols add clomiphene or tamoxifen, which cost an additional $60 to $150 per course from grey-market sources, or more through a physician's prescription.

The hidden cost is the quality problem. Because no regulatory body inspects these products, the purity and actual dosage you receive depend entirely on the vendor's honesty. The Van Wagoner JAMA analysis found dose discrepancies as high as 90 percent above or below the stated amount (1). Buying a third-party certificate of analysis from a vendor's website provides some assurance, but those certificates are not always from accredited ISO 17025 labs and can be fabricated.

What Are the Medical Risks That Affect Total Cost?

The financial cost of a SARM cycle does not end at the purchase price. Medical consequences add up quickly, particularly liver toxicity and hormonal suppression.

Liver toxicity. Multiple case reports document drug-induced liver injury (DILI) from SARMs. A 2021 case series in the Annals of Internal Medicine described a 49-year-old man with acute cholestatic hepatitis after 4 weeks of LGD-4033 at 10 mg/day; biopsy confirmed drug-induced cholestasis (3). Liver function tests, consultations, and imaging can add several hundred to several thousand dollars to a cycle's real cost.

Hormonal suppression. RAD-140 and LGD-4033 both suppress the hypothalamic-pituitary-gonadal (HPG) axis at marketed doses. A phase I trial of LGD-4033 in healthy men (N=76) by Basaria et al. showed dose-dependent suppression of total testosterone, free testosterone, FSH, and LH, with levels not fully recovered at the 5-week post-dose follow-up (4). Suppression that persists for months may require endocrine evaluation, which adds physician visit and lab costs.

Cardiovascular signals. Cardarine (GW-501516) is not technically a SARM but is frequently co-marketed with SARMs. It is a PPAR-delta agonist that was abandoned by GlaxoSmithKline after animal carcinogenicity studies showed dose-dependent tumor growth in multiple organs (5). The Endocrine Society's 2020 clinical practice guideline on androgen therapy explicitly advises against SARMs outside of approved clinical trials, noting that long-term safety data in humans are absent (6).

HealthRX Real-Cost Framework for a 12-Week SARM Stack:

• Product cost: $300 to $600
• Third-party lab testing (optional but advised): $50 to $120
• Post-cycle therapy drugs: $60 to $150
• Baseline and follow-up labs (AST, ALT, total testosterone, LH, FSH, lipids): $80 to $200 out of pocket if uninsured
• Estimated hepatologist or endocrinologist visit if adverse event occurs: $250 to $600 per visit
• Realistic total range: $740 to $1,670 per cycle

That range overlaps substantially with the cost of 3 to 6 months of supervised, physician-prescribed testosterone replacement therapy or compounded anavar through a licensed telehealth provider.

Cost of Compounded Anavar (Oxandrolone)

Compounded anavar is a real FDA-scheduled controlled substance (Schedule III) that requires a prescription from a licensed provider. That means it can only be obtained through a physician evaluation and must be prepared by a licensed 503A or 503B pharmacy. The regulatory framework around it is well defined, which is precisely what makes it different from a grey-market SARM.

Brand-name anavar (oxandrolone) from commercial manufacturers typically costs $300 to $800 per month at retail pharmacies for doses used in body-composition contexts (10 to 40 mg/day). Compounded oxandrolone from a licensed 503B pharmacy, dispensed through a telehealth provider, typically runs $80 to $200 per month depending on dose and pharmacy (7).

The dosing context matters. In clinical use, oxandrolone has documented efficacy at doses of 20 mg/day for preserving lean mass in HIV-associated wasting and recovery from burns. A controlled trial published in the Journal of Clinical Endocrinology and Metabolism (N=262 HIV-positive men) showed oxandrolone 20 mg/day for 12 weeks produced 1.8 kg greater lean mass gain versus placebo (P<0.001) (8). Those are controlled, verified doses from quality-assured drug products, not the inconsistent milligrams in a grey-market capsule.

Because oxandrolone is hepatotoxic at higher doses (particularly above 20 mg/day for prolonged periods), prescribing providers monitor liver enzymes at baseline and at 6 to 8-week intervals. That monitoring is built into the cost of responsible use. The overall monthly spend, including labs and provider visits, typically runs $150 to $350.

As the American Society for Bone and Mineral Research summarized in commentary on anabolic agents, "supervised anabolic therapy with pharmacokinetically defined compounds offers a fundamentally different risk-benefit calculus than self-administered, uncharacterized research chemicals" (6).

How SARMs Costs Compare to Prescription Testosterone (TRT)

Standard testosterone replacement therapy (TRT) is FDA-approved, has 70+ years of safety data, and costs far less than most people expect through modern telehealth.

Compounded testosterone cypionate injections through a licensed telehealth provider run $30 to $80 per month for typical TRT doses of 100 to 200 mg per week. Testosterone enanthate is similarly priced. Topical testosterone gels or creams cost $60 to $120 per month compounded. These prices include the drug itself; provider consultation and labs add $50 to $150 per quarter at most telehealth platforms.

The TRAVERSE trial (N=5,246 men with hypogonadism aged 45 to 80) established that testosterone therapy does not increase major adverse cardiovascular events compared to placebo over a median follow-up of 33 months, which resolved a long-standing safety concern (9). No comparable large-scale cardiovascular safety trial exists for any SARM compound.

For body-composition goals specifically, testosterone at physiologic-to-supraphysiologic doses has a documented dose-response relationship with lean mass and strength. A landmark dose-finding study by Bhasin et al. in NEJM (N=61 healthy young men) showed graded increases in fat-free mass of 3.2 kg at 300 mg/week and 7.9 kg at 600 mg/week over 20 weeks, confirming the anabolic dose-response at doses above standard TRT (10).

SARMs have not replicated that effect size in controlled human trials. The LGD-4033 phase I data showed modest lean mass increases (approximately 1.21 kg) at the highest tested dose (1 mg/day) in a 21-day window, with unclear durability (4).

Legal and Regulatory Considerations That Affect Your Purchase Decision

Buying SARMs is not automatically a criminal act for the individual consumer in the United States, but the legal status is more complicated than vendor marketing suggests.

SARMs are not scheduled controlled substances under the Controlled Substances Act as of mid-2025, which is why they remain in a grey zone. However, the FDA classifies them as unapproved new drugs and has stated that introducing them into interstate commerce is illegal. The SARMs Control Act, introduced in Congress multiple times, would schedule SARMs alongside anabolic steroids as Schedule III controlled substances; that legislation has not passed as of July 2025, but it signals the regulatory direction.

Competitive athletes face additional jeopardy. The World Anti-Doping Agency (WADA) added all SARMs to its Prohibited List in 2008 and has maintained that prohibition. WADA's 2024 Prohibited List classifies SARMs under Section S1.2 (Other Anabolic Agents), alongside clenbuterol and selective estrogen receptor modulators used in a doping context (11).

Military personnel carry even higher risk. The Department of Defense has confirmed that SARMs use can result in adverse action under the Uniform Code of Military Justice, and positive urinalysis panels exist at several military testing laboratories.

For the individual patient seeking body-composition support, the practical upshot is direct: no licensed physician in the United States can legally prescribe a SARM for body-composition purposes, because no SARM has an approved indication. Any telehealth platform offering "SARM prescriptions" is either mislabeling the product or operating outside legal bounds.

Who Is a Legitimate Candidate for Anabolic Body-Composition Therapy?

Adults with documented hormonal deficiencies, muscle-wasting conditions, or clinically meaningful body-fat redistribution may be appropriate candidates for supervised anabolic therapy.

Criteria that support a prescribing evaluation include: total testosterone below 300 ng/dL on two morning measurements per American Urological Association guidelines, signs of hypogonadism (fatigue, loss of lean mass, low libido), or specific diagnoses such as HIV-associated wasting, glucocorticoid-induced myopathy, or surgical menopause with refractory body-composition changes.

The Endocrine Society's 2018 guideline on testosterone therapy in women notes that low-dose testosterone (targeting free testosterone in the physiologic premenopausal range) may improve sexual function and muscle composition in postmenopausal women, with the caveat that long-term breast safety data beyond 24 months are limited (12).

For women specifically, compounded oxandrolone at doses of 2.5 to 5 mg/day is sometimes prescribed off-label for lean mass preservation during GLP-1-facilitated weight loss. The rationale is that aggressive caloric restriction plus GLP-1 receptor agonists can reduce lean mass alongside fat mass, and low-dose anabolic support may preserve muscle. No large RCT has confirmed this combination protocol as of this writing, and it remains a clinical judgment call requiring informed consent.

How to Evaluate a Provider Offering Anabolic Body-Composition Therapy

Not all telehealth providers offering compounded anavar or TRT operate with the same standards. The following signals distinguish quality providers from those cutting corners.

A legitimate provider will draw baseline labs before prescribing, at minimum: complete metabolic panel (CMP), complete blood count (CBC), lipid panel, and a morning total testosterone with free testosterone, LH, FSH, and SHBG for TRT. For oxandrolone, hepatic function tests at baseline and follow-up are non-negotiable.

Pharmacy verification matters. Compounded drugs should come from a pharmacy registered as a 503B outsourcing facility with the FDA, which is subject to current Good Manufacturing Practice (cGMP) inspection. The FDA maintains a publicly searchable list of registered 503B facilities (13).

Prescribers should be licensed in the patient's state of residence. Board-certified physicians in internal medicine, endocrinology, or urology are the most appropriate specialists for androgen prescribing; nurse practitioners and physician assistants may prescribe in states where their scope allows.

The Endocrine Society's position statement on testosterone therapy states: "Testosterone therapy should be initiated only after a complete diagnostic evaluation and with ongoing monitoring to assess efficacy and safety" (6).

Practical Cost Comparison Summary

For a body-composition-focused adult evaluating options, the real monthly costs look like this:

Grey-market SARMs (unregulated): $40 to $150 per compound, no monitoring included, quality unverified, no physician oversight, potential legal exposure for vendors.

Compounded testosterone cypionate (TRT, physician-supervised): $30 to $80 for medication; add $40 to $50 per month amortized for quarterly labs and visits. Total: approximately $70 to $130 per month.

Compounded oxandrolone (physician-supervised): $80 to $200 for medication; add lab monitoring costs. Total: approximately $130 to $350 per month.

Brand-name testosterone products (e.g., Xyosted, AndroGel): $200 to $600 per month before insurance; with insurance and copay programs, $0 to $50 for eligible patients.

The compounded supervised options cost more than a single SARM bottle. They cost significantly less once you factor in PCT, labs drawn after adverse events, and the non-trivial probability of getting a mislabeled product that delivers either nothing or an unintended compound at an unverified dose.